GO:0060702 negative regulation of endoribonuclease activity: RNA Stability Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060702 describes any process that decreases the rate, frequency or extent of endoribonuclease activity, the hydrolysis of internal RNA phosphodiester bonds.
• Endoribonuclease activity is executed by enzymes such as IRE1α, RNase H2, MazF and RNase A family members, and its negative regulation protects cells from inappropriate RNA cleavage.
• Loss of negative regulation of endoribonuclease activity can trigger dsRNA accumulation, innate immune activation and cell death, as shown for IRE1α in triple-negative breast cancer.
• Mutations in genes encoding RNases or their regulators, including TREX1, RNASEH2A/B/C, SAMHD1 and ADAR, are linked to Aicardi-Goutières syndrome and interferon-related biomarkers.
• Negative regulation of endoribonuclease activity is relevant to cancer, autoinflammation, β-cell proteostasis and lipid metabolism, making it a target for CRISPR knockout, point-mutation and knock-in models.
• CRISPR-based knockout, point mutation, knock-in and overexpression cell models, combined with RNA-seq, Ribo-seq and proteomics, are key methods to dissect this regulatory process.
Description
GO:0060702, negative regulation of endoribonuclease activity, is a biological process term that captures any mechanism that decreases the rate, frequency or extent of endoribonuclease catalysis, i.e. the hydrolysis of ester linkages within RNA by creating internal breaks. Endoribonucleases are enzymes that cleave RNA internally, and their activity must be tightly controlled because uncontrolled RNA cleavage can destroy essential transcripts, release immunostimulatory RNA fragments and trigger cell death. The importance of this regulatory process is illustrated by IRE1α, an endoribonuclease whose activity is negatively regulated to silence double-stranded RNA and prevent taxane-induced pyroptosis in triple-negative breast cancer. Similarly, RNase H2 and other RNases are subject to regulation that prevents inappropriate nucleic acid accumulation and autoinflammatory signaling in Aicardi-Goutières syndrome. For researchers, GO:0060702 provides a framework to study how cells balance RNA degradation and RNA stability, and how disruption of this balance contributes to cancer, autoimmunity and metabolic disease. Understanding negative regulation of endoribonuclease activity therefore requires integrating enzymology, RNA biology and disease genetics, and it is increasingly studied with CRISPR-based cell models and transcriptome-wide methods.
negative regulation of endoribonuclease activity At A Glance
| GO ID | GO:0060702 |
|---|---|
| GO term | negative regulation of endoribonuclease activity |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency or extent of internal RNA cleavage by endoribonucleases |
| Biological context | RNA stability, innate immune silencing, stress responses, cell survival |
| Representative regulators | IRE1α, RNase H2, MazF, RNase A family, TRIM25-related pathways |
| Disease relevance | Triple-negative breast cancer, Aicardi-Goutières syndrome, metabolic and inflammatory disorders |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, Ribo-seq, proteomics |
What Is GO:0060702?
In simple terms, GO:0060702 describes the processes that put the brakes on enzymes that cut RNA internally. According to the QuickGO definition, it is any process that decreases the rate, frequency or extent of the catalysis of the hydrolysis of ester linkages within ribonucleic acid by creating internal breaks. This is a biological_process term, meaning it describes a series of molecular events rather than a static structure or a single molecular function. The term has no synonyms in QuickGO. It is the negative counterpart of positive regulation of endoribonuclease activity and is distinct from regulation of exonuclease activity, which removes nucleotides from RNA ends rather than creating internal breaks. Negative regulation can be achieved by direct inhibition of the endoribonuclease, by sequestration of the enzyme or its substrate, by post-translational modification, or by degradation of the enzyme, and it is essential for preventing inappropriate RNA cleavage and downstream innate immune activation.
Why Is negative regulation of endoribonuclease activity Important in Cell Biology?
Negative regulation of endoribonuclease activity is important because endoribonucleases are powerful enzymes that can rapidly degrade RNA and generate immunostimulatory fragments, so their activity must be restrained to maintain cellular homeostasis. When this negative regulation fails, cells can accumulate double-stranded RNA and activate innate immune pathways, leading to pyroptosis or autoinflammatory disease. Conversely, excessive negative regulation may stabilize oncogenic or misfolded transcripts and support cancer cell survival. Studying GO:0060702 therefore helps explain how cells balance RNA turnover and RNA protection, and it provides a mechanistic basis for therapeutic strategies targeting RNA-cleaving enzymes and their regulators.
• Prevents inappropriate cleavage of essential mRNAs and non-coding RNAs by endoribonucleases.
• Limits accumulation of immunostimulatory dsRNA and prevents innate immune activation.
• Protects pancreatic β-cells from proinsulin misfolding and programmed cell death.
• Supports cancer cell survival and growth through regulation of stress-response RNases.
• Contributes to lipid metabolism reprogramming in cancer via IRE1α-dependent decay.
• Is linked to Aicardi-Goutières syndrome and interferon-related biomarkers.
• Modulates the Fcγ receptor-stimulating activity of RNA-containing immune complexes.
• Provides a target for CRISPR knockout, point-mutation and knock-in studies of RNA stability.
• Helps interpret transcriptomic and Ribo-seq data by explaining RNA degradation signatures.
• Informs development of RNA-targeting therapeutics and biomarker panels.
What Happens During negative regulation of endoribonuclease activity?
Recognition of the endoribonuclease substrate
In simple terms: First, the cell must recognize which RNA-cutting enzyme is active and what RNA it is targeting.
Negative regulation begins with the cell sensing the presence of an active endoribonuclease and its RNA substrate. For example, IRE1α is an endoribonuclease that can cleave double-stranded RNA, and its activity is negatively regulated to silence dsRNA and prevent taxane-induced pyroptosis in triple-negative breast cancer. In Escherichia coli, the mRNA endonuclease MazF recognizes specific RNA sequences, and its activity is subject to regulation that controls substrate recognition and cleavage. This step ensures that negative regulation is targeted to the appropriate enzyme and RNA context rather than globally suppressing all RNA cleavage.
Direct inhibition or sequestration of the endoribonuclease
In simple terms: The cell can block the RNA-cutting enzyme directly or lock it away so it cannot reach RNA.
Once the endoribonuclease is recognized, negative regulation can occur through direct inhibition or sequestration. RNase H2 and other RNases involved in nucleic acid metabolism are regulated to prevent inappropriate RNA cleavage and autoinflammatory signaling, as seen in Aicardi-Goutières syndrome where mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1 and ADAR are associated with interferon-related biomarkers. In the context of RNA-containing immune complexes, RNase activity is positively and negatively regulated to modulate Fcγ receptor-stimulating activity. These examples show that sequestration or inhibition of endoribonucleases is a central mechanism of GO:0060702.
Post-translational and transcriptional control of endoribonuclease regulators
In simple terms: The cell can also adjust the levels or modifications of proteins that control the RNA-cutting enzyme.
Negative regulation of endoribonuclease activity often involves post-translational modifications or changes in the abundance of regulatory proteins. TRIM25 promotes cell survival and growth of hepatocellular carcinoma through targeting the Keap1-Nrf2 pathway, illustrating how regulatory proteins can indirectly influence RNA-cleaving enzyme activity and stress responses. In pancreatic β-cells, Bax Inhibitor-1 preserves proteostasis by limiting proinsulin misfolding and programmed cell death, a process that can involve regulation of RNA-cleaving enzymes and stress pathways. These regulatory layers ensure that endoribonuclease activity is tuned to the physiological state of the cell.
Downstream consequences for RNA stability and innate immunity
In simple terms: When the RNA-cutting enzyme is restrained, RNA is preserved and immune alarms are avoided.
The ultimate outcome of negative regulation of endoribonuclease activity is preservation of RNA molecules and avoidance of inappropriate innate immune activation. IRE1α-mediated silencing of dsRNA prevents taxane-induced pyroptosis in triple-negative breast cancer, demonstrating that negative regulation of an endoribonuclease can directly determine cell fate. In Aicardi-Goutières syndrome, impaired regulation of RNases and related enzymes leads to interferon-related biomarker signatures, linking loss of negative regulation to autoinflammation. In cancer, regulated IRE1α-dependent decay (RIDD) reprograms lipid metabolism, showing that controlled endoribonuclease activity can also shape metabolic pathways. Thus, GO:0060702 integrates RNA stability, immunity and metabolism.
Key Genes Involved in GO:0060702 negative regulation of endoribonuclease activity
The following genes and proteins are experimentally linked to negative regulation of endoribonuclease activity or to the endoribonucleases whose activity is regulated.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IRE1α (ERN1) | Endoribonuclease in the unfolded protein response; its activity is negatively regulated to silence dsRNA | Triple-negative breast cancer, pyroptosis, lipid metabolism |
| RNase H2 (RNASEH2A/B/C) | Ribonuclease that removes ribonucleotides from DNA; regulated to prevent autoinflammation | Aicardi-Goutières syndrome, interferon biomarkers |
| TREX1 | Exonuclease involved in nucleic acid metabolism; mutations linked to autoinflammation | Aicardi-Goutières syndrome |
| SAMHD1 | dNTPase and nucleic acid regulator; mutations cause autoinflammatory disease | Aicardi-Goutières syndrome |
| ADAR | RNA editing enzyme; mutations associated with interferon-related disease | Aicardi-Goutières syndrome |
| MazF | mRNA endonuclease in E. coli; activity is regulated by substrate recognition | Bacterial RNA cleavage mechanisms |
| RNase A family | Secreted ribonucleases that cleave RNA; activity modulated in immune complexes | Fcγ receptor-stimulating activity |
| TRIM25 | E3 ubiquitin ligase targeting Keap1-Nrf2; promotes cell survival | Hepatocellular carcinoma |
| Keap1 | Substrate adaptor for Nrf2 degradation; regulated by TRIM25 | Hepatocellular carcinoma |
| Nrf2 | Transcription factor controlling antioxidant response; regulated by Keap1 | Hepatocellular carcinoma |
| Bax Inhibitor-1 (TMBIM6) | Preserves pancreatic β-cell proteostasis and limits programmed cell death | β-cell survival, proinsulin misfolding |
| Proinsulin (INS) | Insulin precursor prone to misfolding; protected by BI-1 | Pancreatic β-cell proteostasis |
| Chromatin remodellers | Genome-wide nucleosome specificity and function in ES cells | Gene regulation context |
| dsRNA sensors | Detect double-stranded RNA and trigger innate immunity | Pyroptosis, cancer |
| Interferon-stimulated genes | Mediate innate immune responses to nucleic acids | Aicardi-Goutières syndrome |
| Lipid metabolism enzymes | Reprogrammed by RIDD in cancer | Cancer metabolism |
| Fcγ receptors | Bind RNA-containing immune complexes; activity modulated by RNase | Immune complex biology |
How Is negative regulation of endoribonuclease activity Regulated?
Negative regulation of endoribonuclease activity is itself regulated at multiple levels. In cancer, IRE1α-dependent decay (RIDD) is controlled to reprogram lipid metabolism, and its negative regulation prevents excessive RNA cleavage. In triple-negative breast cancer, IRE1α silences dsRNA to prevent taxane-induced pyroptosis, showing that the negative regulation of this endoribonuclease is critical for cell survival under chemotherapy. In autoinflammatory disease, mutations in TREX1, RNASEH2A/B/C, SAMHD1 and ADAR disrupt the normal regulation of nucleic acid metabolism, leading to interferon-related biomarker signatures. RNase activity in RNA-containing immune complexes is also positively and negatively regulated to modulate Fcγ receptor-stimulating activity. These examples indicate that negative regulation of endoribonuclease activity is integrated with stress responses, immune signaling and metabolic pathways.
negative regulation of endoribonuclease activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IRE1α (ERN1) | Triple-negative breast cancer, pyroptosis, lipid metabolism | Knockout and point-mutation cell models in breast cancer lines |
| RNASEH2A/B/C | Aicardi-Goutières syndrome, interferon biomarkers | Knock-in of patient mutations in human cell lines |
| TREX1 | Aicardi-Goutières syndrome | Knockout and knock-in models in immune cells |
| SAMHD1 | Aicardi-Goutières syndrome | Knockout and point-mutation models |
| ADAR | Aicardi-Goutières syndrome | Knock-in of disease variants |
| TRIM25 | Hepatocellular carcinoma | Overexpression and knockout in liver cancer cells |
| Bax Inhibitor-1 (TMBIM6) | Pancreatic β-cell proteostasis | Knockout and overexpression in β-cell lines |
Cancer and chemotherapy resistance
In triple-negative breast cancer, IRE1α silences dsRNA to prevent taxane-induced pyroptosis, and negative regulation of this endoribonuclease activity is essential for cancer cell survival during chemotherapy. Regulated IRE1α-dependent decay also reprograms lipid metabolism in cancer, linking negative regulation of endoribonuclease activity to metabolic adaptation. TRIM25 promotes hepatocellular carcinoma cell survival and growth through the Keap1-Nrf2 pathway, providing another example of how regulatory proteins can influence RNA stress responses and tumor progression.
Autoinflammatory and interferon-related disease
Aicardi-Goutières syndrome is associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1 and ADAR, and these mutations lead to interferon-related biomarker signatures. This demonstrates that loss of negative regulation of endoribonuclease activity or related nucleic acid metabolism can cause autoinflammation. RNase activity also modulates the Fcγ receptor-stimulating activity of RNA-containing immune complexes, further connecting endoribonuclease regulation to immune complex biology.
Metabolic and proteostasis disorders
Bax Inhibitor-1 preserves pancreatic β-cell proteostasis by limiting proinsulin misfolding and programmed cell death, a process that can involve regulation of RNA-cleaving enzymes and stress pathways. In cancer, RIDD-mediated reprogramming of lipid metabolism shows that negative regulation of endoribonuclease activity can influence metabolic disease and cancer metabolism. These findings suggest that dysregulation of GO:0060702 may contribute to metabolic and proteostasis-related disorders.
From negative regulation of endoribonuclease activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IRE1α negative regulation increase dsRNA and pyroptosis? | IRE1α knockout and point-mutation cell models |
| Do RNASEH2 mutations impair negative regulation of endoribonuclease activity? | RNASEH2A/B/C knock-in of patient mutations |
| Does TRIM25 overexpression alter Keap1-Nrf2 and RNA stress responses? | TRIM25 overexpression and knockout in hepatocellular carcinoma cells |
| Does Bax Inhibitor-1 protect β-cells from proinsulin misfolding? | BI-1 knockout and overexpression in pancreatic β-cell lines |
| How does RIDD reprogram lipid metabolism in cancer? | IRE1α knockout and tagged knock-in in cancer cell lines |
| Does RNase activity modulate immune complex signaling? | RNase overexpression and knockout in immune cell models |
How to Study the negative regulation of endoribonuclease activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | RNA abundance and degradation signatures | Detecting protection or degradation of transcripts |
| Ribo-seq | Translation efficiency and ribosome occupancy | Assessing impact of endoribonuclease regulation on translation |
| Proteomics | Protein abundance and modifications | Identifying regulators of endoribonuclease activity |
| dsRNA imaging | Double-stranded RNA accumulation | Monitoring innate immune activation and pyroptosis |
| Biochemical RNase assays | Enzymatic cleavage activity | Defining substrate recognition and regulation |
| Immune complex assays | Fcγ receptor-stimulating activity | Measuring RNase modulation of immune complexes |
| Interferon biomarker profiling | Interferon-stimulated gene expression | Studying Aicardi-Goutières syndrome |
| CRISPR screening | Gene essentiality and pathway interactions | Identifying regulators of endoribonuclease activity |
Transcriptome-wide RNA stability profiling
RNA-seq and Ribo-seq can measure changes in RNA abundance and translation efficiency when negative regulation of endoribonuclease activity is perturbed. For example, IRE1α-mediated silencing of dsRNA and RIDD-mediated reprogramming of lipid metabolism can be monitored by transcriptomic changes in cancer cells. These methods help identify which RNAs are protected or degraded when endoribonuclease activity is negatively regulated.
Proteomics and post-translational modification analysis
Proteomics can detect changes in endoribonuclease abundance and post-translational modifications that mediate negative regulation. TRIM25 targeting of the Keap1-Nrf2 pathway illustrates how ubiquitin-proteasome regulation can influence stress responses and RNA-cleaving enzyme activity. Bax Inhibitor-1-dependent preservation of β-cell proteostasis can also be studied by proteomic profiling of proinsulin misfolding and programmed cell death markers.
Imaging and dsRNA detection
Imaging-based assays can visualize dsRNA accumulation and cell death when negative regulation of endoribonuclease activity is lost. In triple-negative breast cancer, IRE1α silences dsRNA to prevent taxane-induced pyroptosis, and dsRNA-specific imaging can reveal whether negative regulation is intact. These approaches are useful for linking molecular changes to cellular phenotypes such as pyroptosis.
Genetic and biochemical assays for RNase regulation
Biochemical assays using purified endoribonucleases such as MazF can define substrate recognition and activity regulation, as shown for the E. coli mRNA endonuclease. RNase activity in RNA-containing immune complexes can be measured to assess positive and negative regulation of Fcγ receptor-stimulating activity. These assays complement cell-based CRISPR models by providing direct enzymatic readouts.
How CRISPR Can Be Used to Study GO:0060702 negative regulation of endoribonuclease activity
Knockout
CRISPR knockout of genes such as IRE1α, RNASEH2A/B/C, TREX1, SAMHD1 or ADAR can reveal whether loss of negative regulation of endoribonuclease activity leads to dsRNA accumulation, interferon signaling or cell death. Knockout models are useful for testing causality between a candidate regulator and RNA stability phenotypes.
Point Mutation
Point-mutation models can mimic disease-associated variants in genes such as RNASEH2A/B/C, TREX1, SAMHD1 or ADAR to study how specific residues affect negative regulation of endoribonuclease activity. These models help distinguish loss-of-function, gain-of-function and separation-of-function effects on RNA cleavage and immune activation.
Knock-in
Knock-in of patient-derived mutations or tagged alleles allows precise study of endoribonuclease regulation in a physiological context. For example, knock-in of Aicardi-Goutières syndrome mutations in RNASEH2 genes can be used to monitor interferon-related biomarkers. Tagged knock-in of IRE1α can help track its localization and activity during stress.
Overexpression
Overexpression of negative regulators such as Bax Inhibitor-1 or TRIM25 can test whether increased negative regulation of endoribonuclease activity protects cells from stress or alters tumor growth. Overexpression models are also useful for studying RNase-mediated modulation of immune complex signaling.
How EDITGENE Supports negative regulation of endoribonuclease activity Research
Researchers studying negative regulation of endoribonuclease activity-related genes often need to determine whether a candidate gene is causally involved in RNA stability, innate immune silencing or disease phenotypes. EDITGENE provides publication-ready CRISPR cell models and bioinformatics services to test these hypotheses with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of endoribonuclease activity research.
Frequently Asked Questions About negative regulation of endoribonuclease activity
What is GO:0060702 negative regulation of endoribonuclease activity?
GO:0060702 is a biological process term describing any process that decreases the rate, frequency or extent of internal RNA cleavage by endoribonucleases.
What genes are involved in negative regulation of endoribonuclease activity?
Genes such as IRE1α (ERN1), RNASEH2A/B/C, TREX1, SAMHD1, ADAR, MazF, TRIM25 and TMBIM6 have been linked to this process or to the endoribonucleases it regulates.
Why is negative regulation of endoribonuclease activity important in cancer?
In triple-negative breast cancer, IRE1α silences dsRNA to prevent taxane-induced pyroptosis, and RIDD reprograms lipid metabolism, showing that negative regulation of endoribonuclease activity affects cancer cell survival and metabolism.
How is negative regulation of endoribonuclease activity linked to autoimmunity?
Mutations in TREX1, RNASEH2A/B/C, SAMHD1 and ADAR are associated with Aicardi-Goutières syndrome and interferon-related biomarkers, indicating that impaired regulation of nucleic acid metabolism can cause autoinflammation.
What experimental models are used to study GO:0060702?
CRISPR knockout, point-mutation, knock-in and overexpression cell models, combined with RNA-seq, Ribo-seq, proteomics and imaging, are commonly used.
What is the role of IRE1α in negative regulation of endoribonuclease activity?
IRE1α is an endoribonuclease whose activity is negatively regulated to silence dsRNA and prevent pyroptosis in triple-negative breast cancer.
How does RNase activity affect immune complexes?
RNase activity positively and negatively regulates the Fcγ receptor-stimulating activity of RNA-containing immune complexes.
Can CRISPR knockout help identify regulators of endoribonuclease activity?
Yes, CRISPR knockout of candidate genes such as IRE1α, RNASEH2A/B/C, TREX1, SAMHD1 and ADAR can reveal their role in RNA stability and immune signaling.
What methods measure negative regulation of endoribonuclease activity?
RNA-seq, Ribo-seq, proteomics, dsRNA imaging, biochemical RNase assays and interferon biomarker profiling are commonly used.
How does Bax Inhibitor-1 relate to endoribonuclease regulation?
Bax Inhibitor-1 preserves pancreatic β-cell proteostasis by limiting proinsulin misfolding and programmed cell death, a process that can involve regulation of RNA-cleaving enzymes and stress pathways.
Conclusion
GO:0060702, negative regulation of endoribonuclease activity, is a critical biological process that controls RNA stability, innate immune silencing and cell fate. Experimental evidence from cancer, autoinflammatory disease and metabolic models shows that disrupting this regulation can lead to dsRNA accumulation, pyroptosis, interferon signatures and metabolic reprogramming. Studying the genes and mechanisms involved requires integrated approaches, including CRISPR knockout, point-mutation, knock-in and overexpression models, together with RNA-seq, Ribo-seq and proteomics. EDITGENE provides these research tools and services to help scientists dissect GO:0060702 and translate findings into therapeutic insights.
References
- 1. Xu L et al.. 2024. IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer.. Cell 187(25):7248-7266.e34 PMID: 39419025
- 2. Naito R et al.. 2023. Positive and negative regulation of the Fcγ receptor-stimulating activity of RNA-containing immune complexes by RNase.. JCI Insight 8(16) PMID: 37432743
- 3. Liu Y et al.. 2020. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway.. Nat Commun 11(1):348 PMID: 31953436
- 4. Rice GI et al.. 2013. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.. Lancet Neurol 12(12):1159-69 PMID: 24183309
- 5. Blanc M et al.. 2024. Bax Inhibitor-1 preserves pancreatic β-cell proteostasis by limiting proinsulin misfolding and programmed cell death.. Cell Death Dis 15(5):334 PMID: 38744890
- 6. Almanza A et al.. 2022. Regulated IRE1α-dependent decay (RIDD)-mediated reprograming of lipid metabolism in cancer.. Nat Commun 13(1):2493 PMID: 35524156
- 7. Zorzini V et al.. 2016. Substrate Recognition and Activity Regulation of the Escherichia coli mRNA Endonuclease MazF.. J Biol Chem 291(21):10950-60 PMID: 27026704
- 8. de Dieuleveult M et al.. 2016. Genome-wide nucleosome specificity and function of chromatin remodellers in ES cells.. Nature 530(7588):113-6 PMID: 26814966
